Our Blood Institute ยท 12 hours ago
PLATELET INTERCEPT COMPONENT TECHNICIAN - EVENINGS (OKLAHOMA CITY, OK)
Our Blood Institute is actively seeking qualified candidates for a rewarding position that is responsible for successfully manufacturing blood and blood components. The role involves ensuring high-quality products that meet FDA requirements for safety, potency, and purity while working as part of a team.
CharityHealth CareNon Profit
Responsibilities
Manufacture Pathogen reduced platelet products (PLAP)
Ensure high quality product that meets FDA requirements for safety, potency and purity
Inspect, verify and label pathogen reduced platelet products
Provide sample platelet products for QC analysis
Perform maintenance and quality control of equipment for pathogen reduced platelets as appropriate
Enter data of platelet products
Seg blood/plasma components as determined by the lead
Verify standard operating procedures as required
Assist in the training of staff
Qualification
Required
High school diploma or GED required
No experience necessary
Good communication skills and professional demeanor
Dependable
Attention to detail
Problem solving ability
Ability to work well with people
Ability to stand for long periods of time
Organizational skills
Dexterity
Flexible schedule
Preferred
Computer skills preferred
Benefits
Health
Dental
Vision
Life insurance
Long term disability
401(k)
Paid time off
$5,000 annual tuition reimbursement
Annual uniform allowance
Holiday pay
Company
Our Blood Institute
Our Blood Institute is the sixth-largest independent blood center in the nation, with 16 donor centers in Oklahoma, Arkansas and Texas.
H1B Sponsorship
Our Blood Institute has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (11)
2024 (4)
2023 (4)
2022 (2)
2021 (3)
Funding
Current Stage
Late StageRecent News
2025-05-17
2025-04-28
Company data provided by crunchbase